TRLV

Trulieve Cannabis Corp.

Medicinal Chemicals & Botanical Products · SIC 2833CIK 1754195Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$1.18B

Net Income FY2025

$(0.12B)

EPS (Basic, as reported)

$-0.58

Net Margin FY2025

-10.3%

ROE FY2025

-10.7%

Total Equity

$1.14B

Shares Out

—

Business description

Trulieve Cannabis Corp. — Medicinal Chemicals & Botanical Products. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 253 → 1,181 +29.3% CAGR

Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue2535229381,2401,1291,1861,181

Cost of revenue(61)(135)(372)(558)(541)(471)(470)

Gross profit192386566682589716711

Selling, general & administrative————(386)(510)(445)

Selling & marketing(59)(119)(215)(285)(240)(258)—

General & administrative(14)(36)(101)(170)(146)(253)—

Total operating expenses(79)(168)(369)(650)(810)(618)(568)

Operating income11321819732(222)98143

Interest expense(9)(20)(35)(80)(82)(62)(63)

Interest & investment income——026——

Other income (expense), net(10)(61)(33)(76)(63)(55)(52)

Pre-tax income104157164(43)(285)4391

Income tax expense(51)(94)(146)(162)(151)(198)(208)

Net income536317(253)(533)(161)(122)

EPS — basic$0.48$0.55$0.13($1.06)($2.28)($0.79)($0.58)

EPS — diluted$0.46$0.53$0.12($1.06)($2.28)($0.79)($0.58)

Shares outstanding — basic (M)110114139188189190191

Shares outstanding — diluted (M)115118147188189190191

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.